Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors

This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).

Inclusion Criteria:

• Diagnosis of Ewing's sarcoma family tumors

Exclusion Criteria:

• Concurrent treatment with any other anti tumor agents